UTK Utek Corp

 

TIDMUTK 
 
 
UTEK Corporation 
16 April 2009 
 
? 
16 April 2009 
 
 
UTEK Corporation 
 
 
Pharmalicensing and ICE Pharma Group Announce the Launch of Genericlicensing.com 
 
 
Tampa, FL, Berks & York, England -- (Business Wire) - April 16, 2009 -- UTEK 
Corporation (NYSE Alternext US & LSE-AIM: UTK), a leading innovation services 
company is pleased to announce the launch of a new website, 
www.genericlicensing.com. The site represents a joint venture between UTEK's 
Pharmalicensing division and ICE Pharma Group. 
 
 
Genericlicensing.com has been developed to become an essential business tool for 
licensing and contract developments for the generic pharmaceutical sector. The 
site provides a comprehensive database of approved, available and in-development 
generic products. 
 
 
There are a number of key features and tool-sets that will now make the task of 
obtaining new generic products easier for paid subscribers: 
 
 
  *  Product detail - all the required data and information for quick decision making 
  *  Product updates - reduce frequent email exchanges with developers 
  *  Offer and counter-offer tools - compile all information in a web based interface 
  for simple evaluation 
  *  Product requests - ask developers if they would consider a new product 
  development 
 
 
 
The site also offers hands-on business development services to complement the 
online activities: 
 
 
  *  Partner surveys - search through the vast network of contacts to find suitable 
  products/partners 
  *  Project planning, initiation and closure - part or all of the licensing process 
  can be outsourced 
  *  Market assessments - a comprehensive country report is essential before entering 
  a market 
 
 
 
Mark McBride, Director of Pharmalicensing, commented, "We are all delighted to 
have entered into this joint venture for the creation of Genericlicensing.com. 
We feel that it will offer a valuable tool for generic companies of all sizes to 
rapidly identify products for licensing from reliable and pre-screened sources 
from around the world. We look forward to working closely with ICE Pharma Group 
to provide these services through Genericlicensing.com for the benefit of all 
companies working in the sector." 
 
 
Asa Cox, Strategic Business Development Director at ICE stated, "Using the power 
of Pharmalicensing's existing platform, tailored to the generics industry, and 
leveraging ICE's expertise, we feel the partnership has created an extremely 
useful business tool. Already we have over 150 subscribers looking for products; 
from both large generic companies and local firms from around the world. We 
believe Genericlicensing.com will become an essential part of the way the 
generics industry does business." 
 
 
For more information see www.genericlicensing.com. 
 
 
About UTEK Corporation 
 
 
UTEKis a leading innovation services company. UTEK's services enable clients to 
become stronger innovators, rapidly source externally developed technologies, 
create value from their intellectual property and gain foresight into 
marketplace and technology developments that affect their business. UTEK is a 
business development company. For more information about UTEK, please visit its 
website at www.utekcorp.com. 
 
 
About Pharmalicensing 
 
 
Pharmalicensing is the premier biopharmaceutical open innovation resource 
designed for life science professionals involved with partnering, licensing and 
business development worldwide. Actively supporting in- and out-licensing 
activities, Pharmalicensing currently provides partnering services to over 200 
client companies around the world. Pharmalicensing is a division of UTEK 
Corporation. For more information, please visit its website at 
www.pharmalicensing.com. 
 
 
About ICE Pharma Group 
 
 
ICE, established in 1998, is a pharmaceutical company which specializes in 
sourcing, manufacturing services and business development in the generics and 
OTC market sectors. ICE started life as a pharmaceutical active ingredients 
(APIs) trading company with an emphasis on the Far East; supporting large 
generic companies with difficult to source and hard to manage APIs. 
 
 
Building on this partner portfolio and a growing client base in Europe and USA, 
ICE vertically integrated into finished formulations, offering both contract 
manufacturing services and registration dossiers. In 2004 ICE made the strategic 
move to transform its manufacturing relationships in to strategic partnerships 
and carefully matched joint ventures; compounding the benefits of its history 
and enabling it to launch its own generic products into select markets. 
 
 
Today the ICE Pharma Group of companies offers a range of services and 
manufacturing options across the generic pharmaceutical market sector utilizing 
its skills, strategic partnerships and licensing network. For more information 
about ICE Pharma Group, please visit its website at www.icepharmagroup.com. 
 
 
Forward-Looking Statements 
 
 
Certain matters discussed in this press release are "forward-looking 
statements." These forward-looking statements can generally be identified as 
such because the context of the statement will include words, such as UTEK or 
ICE Pharma Group "expects," "should," "believes," "anticipates" or words of 
similar import. Similarly, statements that describe UTEK's or ICE Pharma Group's 
future plans, objectives or goals are also forward-looking statements. Such 
forward-looking statements are subject to certain risks and uncertainties, which 
could cause actual results to differ materially from those currently 
anticipated. Although UTEK and ICE Pharma Group believe the expectations 
reflected in any forward-looking statements are based on reasonable assumptions, 
it cannot give any assurance that its expectations will be attained. 
Shareholders, potential investors and other readers are urged to consider these 
factors carefully in evaluating any forward-looking statements. Certain factors 
could cause results and conditions to differ materially from those projected in 
these forward-looking statements, and some of these factors are discussed below. 
These factors are not exhaustive. New factors, risks and uncertainties may 
emerge from time to time that may affect the forward-looking statements made 
herein. These forward-looking statements are only made as of the date of this 
press release and UTEK and ICE Pharma Group do not undertake any obligation to 
publicly update such forward-looking statements to reflect subsequent events or 
circumstances. 
 
 
UTEK's operating results could fluctuate significantly due to a number of 
factors. These factors include, levels of consulting activity, variability in 
the growth rate of our business, consultant utilization rates, consultant and 
project billing rates, and number of revenue-generating professionals; our 
ability to expand our service offerings; that we successfully integrate the 
businesses we acquire; challenging financial conditions, including those in the 
credit markets, the number of transactions and engagements that are completed 
each quarter, the value of individual contracts and transactions, the timing of 
the recognition and the magnitude of unrealized and realized gains and losses of 
companies in its portfolio, UTEK's dependence on the performance of its 
operating divisions as well as the companies in its portfolio, the possibility 
that advances in technology could render the technologies it has transferred 
obsolete, the loss of technology licenses by companies in its portfolio, the 
degree to which it encounters competition in its markets, the volatility of the 
stock market and the volatility of the valuations of the companies it has 
invested in as it relates to its realized and unrealized gains and losses, the 
concentration of investments in a small number of companies, marketplace demand 
for innovation consulting services as well as other general economic conditions. 
For more information on UTEK and for a more complete discussion of the risks 
pertaining to an investment in UTEK, please refer to UTEK's filings with the 
Securities and Exchange Commission. 
 
 
+---------------------------------------+ 
| Contacts:                             | 
+---------------------------------------+ 
| UTEK Corporation & Pharmalicensing,   | 
| Ltd                                   | 
+---------------------------------------+ 
| USA:                                  | 
+---------------------------------------+ 
| Allen & Caron, Inc.                   | 
+---------------------------------------+ 
| Brian Kennedy                         | 
+---------------------------------------+ 
| brian@allencaron.com                  | 
+---------------------------------------+ 
| 212-691-8087                          | 
+---------------------------------------+ 
 
 
 
 
+----------------------------------+ 
| ICE Pharma Group                 | 
+----------------------------------+ 
| Asa Cox                          | 
+----------------------------------+ 
| +44 (0) 870-752-4105             | 
+----------------------------------+ 
|                                  | 
+----------------------------------+ 
| Genericlicensing.com             | 
+----------------------------------+ 
| Delia Freeman                    | 
+----------------------------------+ 
| +44 (0) 870-752-4105             | 
+----------------------------------+ 
| delia.freeman@icepharmagroup.com | 
+----------------------------------+ 
 
 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 NRAIAMBTMMJBTIL 
 

Utek Corp (LSE:UTK)
Historical Stock Chart
From May 2024 to Jun 2024

Utek Corp (LSE:UTK)
Historical Stock Chart
From Jun 2023 to Jun 2024